We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,947

USPTO Patent Eligibility Guidance In View Of CellzDirect And Sequenom
  • Foley & Lardner LLP
  • USA
  • July 18 2016

On July 14, 2016, the USPTO issued a Memorandum to the Patent Examining Corps on patent eligibility in view of recent court decisions. The July 2016


Can You Identify Your Trade Dress?
  • Foley & Lardner LLP
  • USA
  • July 18 2016

Trade dress is a type of trademark intellectual property right that can protect almost any unique identifying aesthetic design used by a company


FTC Battles Hospital Mergers: What to Watch for in this Summer’s High-Profile Appeals
  • Foley & Lardner LLP
  • USA
  • July 18 2016

In a town that is no stranger to landmark hospital merger cases, last month a Chicago federal judge denied the Federal Trade Commission's (FTC


En Banc CAFC Requires UCC Sale For On Sale Bar
  • Foley & Lardner LLP
  • USA
  • July 19 2016

In an en banc decision issued in The Medicines Company v. Hospira, Inc., the Federal Circuit determined that in order for a commercial transaction to


Janssen Seeks Injunction Against Remicade Biosimilar Based On Cell Culture Patent
  • Foley & Lardner LLP
  • USA
  • July 14 2016

In a complaint filed June 14, 2016, Janssen Biotech Inc. seeks a preliminary injunction that would bar Celltrion and Hospira from selling the


Federal Circuit’s recent primer on patent-eligibility
  • Foley & Lardner LLP
  • USA
  • July 6 2016

A method of producing a desired population of multi-cryopreserved hepatocytes was held to be patent-eligible because the challenged claims did not


CAFC Finds Cryopreservation Method Patent Eligible
  • Foley & Lardner LLP
  • USA
  • July 7 2016

The Federal Circuit ruled that the cryopreservation methods at issue in Rapid Litigation Mgmt. Ltd. v. CellzDirect Inc., are patent eligible under 35


The PRICED Act Would Expedite Biosimilar Market Entry
  • Foley & Lardner LLP
  • USA
  • July 12 2016

Although the 12-year exclusivity period for original biologic products was a heavily negotiated provision of the Biologics Price Competition and


Can FDA Implement The BPCIA As The CAFC Suggested?
  • Foley & Lardner LLP
  • USA
  • July 21 2016

In Amgen v. Apotex, the Federal Circuit held that under the Biologics Price Competition and Innovation Act (“BPCIA”), “an applicant must provide a


The Impact of Justice Scalia’s Passing on Pending Supreme Court Cases
  • Foley & Lardner LLP
  • USA
  • February 22 2016

The country was shocked to hear of the recent passing of Supreme Court Justice Antonin Scalia. Legal scholars and political commentators have since